We are live on ! Find out more
VVOS icon

Vivos Therapeutics
VVOS

19 hedge funds and large institutions have $434K invested in Vivos Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

19% more funds holding

Funds holding: 16 → 19 (+3)

4.76% less ownership

Funds ownership: 10.25% → 5.5% (-4.8%)

33% less capital invested

Capital invested by funds: $647K → $434K (-$213K)

Holders
19
Holders Change
+3
Holders Change %
+18.75%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$50.5K
2
TWP
Triad Wealth Partners
Kansas
+$6.87K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$2.44K
4
Osaic Holdings
Osaic Holdings
Arizona
+$2.19K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.35K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$500K
2
NFSG
Newbridge Financial Services Group
Florida
-$1.65K
3
Wells Fargo
Wells Fargo
California
-$34
Name Holding Trade Value Shares
Change 		Change in
Stake
SWIG
1
Strategic Wealth Investment Group
Kentucky
$304K +$314K +128,789 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$45.9K +$50.5K +20,691 New
Commonwealth Equity Services
3
Commonwealth Equity Services
Massachusetts
$36K +$2.44K +1,000 +7%
Vanguard Group
4
Vanguard Group
Pennsylvania
$23.5K – – –
TWP
5
Triad Wealth Partners
Kansas
$6.26K +$6.87K +2,818 New
Credit Agricole
6
Credit Agricole
France
$5.25K – – –
TRCT
7
Tower Research Capital (TRC)
New York
$5.07K +$1.35K +554 +32%
NFSG
8
Newbridge Financial Services Group
Florida
$2.83K -$1.65K -675 -35%
Osaic Holdings
9
Osaic Holdings
Arizona
$1.99K +$2.19K +898 New
S
10
SignatureFD
Georgia
$1.21K – – –
BTI
11
Blue Trust Inc
Georgia
$773 – – –
Group One Trading
12
Group One Trading
Illinois
$506 – – –
Bank of America
13
Bank of America
North Carolina
$229 +$56 +23 +29%
Morgan Stanley
14
Morgan Stanley
New York
$151 +$2 +1 +1%
KA
15
Kozak & Associates
Colorado
$118 – – –
GRP
16
Global Retirement Partners
California
$51 – – –
TWC
17
TD Waterhouse Canada
Ontario, Canada
$28 +$29 +12 New
SPIA
18
Steward Partners Investment Advisory
New York
$18 – – –
AC
19
Armistice Capital
New York
– -$500K -103,582 Closed
Wells Fargo
20
Wells Fargo
California
– -$34 -7 Closed

VVOS Hedge Fund Activity: Q2 2024 in Review

19 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q2 2024, worth a combined $434K — down 33% from $647K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VVOS positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $50.5K. The largest seller was Armistice Capital, exiting entirely with an estimated $500K sold.

  • 19 institutional investors held Vivos Therapeutics (VVOS) as of Q2 2024, up from 16 in Q1 2024.
  • Funds reported $434K of Vivos Therapeutics stock for Q2 2024, down 33% quarter-over-quarter.
  • 5 funds opened new Vivos Therapeutics positions in Q2 2024 and 2 closed out, a net change of +3 holders.
  • The largest Vivos Therapeutics buyer in Q2 2024 was Geode Capital Management, an estimated $50.5K added.
  • The largest Vivos Therapeutics seller in Q2 2024 was Armistice Capital, an estimated $500K sold.

Based on aggregated 13F filings for Q2 2024.